» Articles » PMID: 36233062

Aplastic Anemia As a Roadmap for Bone Marrow Failure: An Overview and a Clinical Workflow

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Oct 14
PMID 36233062
Authors
Affiliations
Soon will be listed here.
Abstract

In recent years, it has become increasingly apparent that bone marrow (BM) failures and myeloid malignancy predisposition syndromes are characterized by a wide phenotypic spectrum and that these diseases must be considered in the differential diagnosis of children and adults with unexplained hematopoiesis defects. Clinically, hypocellular BM failure still represents a challenge in pathobiology-guided treatment. There are three fundamental topics that emerged from our review of the existing data. An exogenous stressor, an immune defect, and a constitutional genetic defect fuel a vicious cycle of hematopoietic stem cells, immune niches, and stroma compartments. A wide phenotypic spectrum exists for inherited and acquired BM failures and predispositions to myeloid malignancies. In order to effectively manage patients, it is crucial to establish the right diagnosis. New theragnostic windows can be revealed by exploring BM failure pathomechanisms.

Citing Articles

Potential of ginsenoside Rg1 to treat aplastic anemia mitogen activated protein kinase pathway in cyclophosphamide-induced myelosuppression mouse model.

Park S World J Stem Cells. 2024; 16(11):900-905.

PMID: 39619872 PMC: 11606349. DOI: 10.4252/wjsc.v16.i11.900.


The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults.

Piekarska A, Pawelec K, Szmigielska-Kaplon A, Ussowicz M Front Immunol. 2024; 15:1378432.

PMID: 38646536 PMC: 11026616. DOI: 10.3389/fimmu.2024.1378432.


Drug Design and Development for Rare Hematologic Diseases.

Fattizzo B, Capecchi M, Motta I Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895940 PMC: 10609818. DOI: 10.3390/ph16101469.


Perspective and Experience of Patients with Aplastic Anemia on Medication Adherence.

Li H, Wu X, Shen J, Lou S Patient Prefer Adherence. 2023; 17:2215-2225.

PMID: 37701429 PMC: 10493145. DOI: 10.2147/PPA.S390409.


A clickable melphalan for monitoring DNA interstrand crosslink accumulation and detecting ICL repair defects in Fanconi anemia patient cells.

Berrada S, Martinez-Balsalobre E, Larcher L, Azzoni V, Vasquez N, Da Costa M Nucleic Acids Res. 2023; 51(15):7988-8004.

PMID: 37395445 PMC: 10450163. DOI: 10.1093/nar/gkad559.


References
1.
Dufour C, Pillon M, Passweg J, Socie G, Bacigalupo A, Franceschetto G . Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2014; 99(10):1574-81. PMC: 4181253. DOI: 10.3324/haematol.2014.106096. View

2.
Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M . Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica. 2009; 94(5):712-9. PMC: 2675684. DOI: 10.3324/haematol.2008.002170. View

3.
Derakhshani A, Hashemzadeh S, Asadzadeh Z, Shadbad M, Rasibonab F, Safarpour H . Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine. Cancers (Basel). 2021; 13(10). PMC: 8155910. DOI: 10.3390/cancers13102414. View

4.
Young N . Current concepts in the pathophysiology and treatment of aplastic anemia. Hematology Am Soc Hematol Educ Program. 2013; 2013:76-81. PMC: 6610029. DOI: 10.1182/asheducation-2013.1.76. View

5.
Zaimoku Y, Takamatsu H, Hosomichi K, Ozawa T, Nakagawa N, Imi T . Identification of an HLA class I allele closely involved in the autoantigen presentation in acquired aplastic anemia. Blood. 2017; 129(21):2908-2916. DOI: 10.1182/blood-2016-11-752378. View